MintNeuro has raised $5 million to scale production of chips for neural devices, according to the company’s funding announcement. Odyssey Ventures led the round, with returning investors and other backers also participating. The investment is intended to move the Imperial College London spinout from technology validation towards commercial scale-up.
How did the company reach this round?
MintNeuro emerged from Imperial College London and develops semiconductors for devices that connect with the brain and nervous system. Such devices range from implants to wearables, according to the source report. The company says its platform is designed for neural applications rather than adapted from general-purpose components.
The source describes a longstanding design choice for this field: adapt existing components or commission custom chips. MintNeuro’s approach is intended to offer purpose-built chips without the lengthy development process associated with bespoke designs. The report places that work amid a shift from research towards clinical and commercial deployment.
What does MintNeuro make?
Its modular semiconductor platform handles neural sensing, signal processing and stimulation, according to the company description in the report. In plain terms, those functions read nerve signals, interpret them and deliver electrical pulses. The architecture is designed to combine these tasks at system level.
The company says this integration can support smaller, lower-power devices and more integrated closed-loop interfaces with the nervous system. Closed-loop systems use signals from the body to inform subsequent stimulation. Potential device areas listed in the source include BCIs, neuromodulation systems, sensory prostheses and bioelectronic medicines.
Who backed the $5 million round?
Odyssey Ventures led the investment, and 33East, JSK Investments and Alumni Ventures participated, according to the report. Empirical Ventures, Jumpspace Ventures and early investors also returned to the round. The source does not give individual contributions, company valuation or the precise share of funding from each backer.
Dorian Haci, Co-Founder and CEO of MintNeuro, said the financing supports a transition from validating the technology to scaling commercially. He described plans for more customer programmes, faster product launches and broader developer access. Those are company ambitions, rather than reported outcomes already achieved.
What has been tested with partners?
MintNeuro has delivered working silicon and reached integration milestones with partners including Motif Neurotech and Amber Therapeutics, the report says. Earlier, the company announced a partnership and multi-year commercial chip supply agreement with Motif. The agreement supports development of a minimally invasive neurostimulator, initially aimed at treatment-resistant depression.
Other neural device companies are evaluating or integrating the platform, while research teams are developing implantable systems that connect directly with the brain and nervous system. The report lists potential applications spanning Parkinson, epilepsy, depression, hearing loss and inflammatory disease. It does not say that MintNeuro’s chips are approved treatments for those conditions.
What happens after the funding?
The company says it will use the investment to grow its engineering team and advance commercial scale-up. Haci’s stated goals include expanding customer programmes and getting chips to more developers. The source does not specify a timetable, hiring total or production target.
Key points from the announcement:
- MintNeuro raised $5 million in a round led by Odyssey Ventures.
- 33East, JSK Investments and Alumni Ventures participated, alongside returning investors.
- The company reports working silicon and integration milestones with partners.
- The investment is intended to support engineering growth and commercial scale-up.
The source does not disclose the company’s valuation or individual investment amounts. It also leaves open how quickly partner evaluations will become commercial deployments. The next concrete indicators will be customer programmes, product launches and further chip integrations. MintNeuro’s announcement frames these as goals supported by the funding, not completed milestones.